Background: There are data to suggest low bone mineral density is disproportionately prevalent among those with psychiatric disorders. This paper aims to review the current evidence on the relationship between depression and bone mineral density, and identify potential mechanisms. Methods: Relevant sources were identified from the Pubmed and Web of Science (ISI) databases from the first relevant publication in 1994 to the present, 2007, using a combination of key words and terms including depression, major depressive disorder, osteoporosis, bone mineral density, hypothalamic-pituitary-adrenal axis, cortisol, cytokines, leptin, antidepressants, selective serotonin reuptake inhibitors, smoking, alcohol, physical activity and diet. Reference lists of chosen articles were further reviewed for associated publications. Results: The possible association between psychiatric illness, in particular depression, and osteoporosis has been the subject of a growing body of research yielding various findings, although most identify some effect on bone. In addition to medication-related processes and/or modifiable lifestyle factors associated with mood disturbances, endocrine and immune alteration secondary to depression may play a pathogenetic role in bone metabolism. Conclusions: Additional longitudinal studies, with the advantage of temporal sequencing, remain to be conducted, as well as research into potential mechanisms surrounding the association. Nevertheless, the current findings are of clinical relevance, given the health burden of both depression and osteoporosis.

Keywords:
Depression, Psychiatric disorders, Bone mineral density (BMD), Osteoporosis
1.
Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436–1442.
2.
Blom MB, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, van Dyck R: Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom 2007;76:289–297.
3.
Papakostas GI, Perlis RH, Seifert C, Fava M: Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom 2007;76:266–270.
4.
Henderson S, Andrews G, Hall W: Australia’s mental health: an overview of the general population survey. Aust NZ J Psychiatry 2000;34:197–205.
5.
Mathers C, Vos T, Stevenson C: The Burden of Disease and Injury in Australia. Canberra, Australian Institute of Health and Welfare, 1999, http://www.aihw.gov.au/publications/health/bdia/bdia.pdf.
6.
Consensus Development Conference: prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107–110.
7.
Henry MJ, Pasco JA, Nicholson GC, Seeman E, Kotowicz MA: Prevalence of osteoporosis in Australian women: Geelong Osteoporosis Study. J Clin Densitom 2000;3:261–268.
8.
Sanders KM, Nicholson GC, Ugoni AM, Pasco JA, Seeman E, Kotowicz MA: Health burden of hip and other fractures in Australia beyond 2000: projections based on the Geelong Osteoporosis Study. Med J Aust 1999;170:467–470.
9.
Niti M, Ng TP, Kua EH, Ho RC, Tan CH: Depression and chronic medical illnesses in Asian older adults: the role of subjective health and functional status. Int J Geriatr Psychiatry 2007;22:1087–1094.
10.
Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, Nemeroff CB, Bremner JD, Carney RM, Coyne JC, Delong MR, Frasure-Smith N, Glassman AH, Gold PW, Grant I, Gwyther L, Ironson G, Johnson RL, Kanner AM, Katon WJ, Kaufmann PG, Keefe FJ, Ketter T, Laughren TP, Leserman J, Lyketsos CG, McDonald WM, McEwen BS, Miller AH, Musselman D, O’Connor C, Petitto JM, Pollock BG, Robinson RG, Roose SP, Rowland J, Sheline Y, Sheps DS, Simon G, Spiegel D, Stunkard A, Sunderland T, Tibbits P Jr, Valvo WJ: Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005;58:175–189.
11.
Mezuk B, Eaton WW, Golden SH: Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 2008;19:1–12.
12.
Ilias I, Alesci S, Gold PW, Chrousos GP: Depression and osteoporosis in men: association or casual link? Hormones (Athens) 2006;5:9–16.
13.
Cizza G, Ravn P, Chrousos GP, Gold PW: Depression: a major, unrecognised risk factor for osteoporosis? Trends Endocrinol Metab 2001;12:198–203.
14.
Schweiger U, Deuschle M, Korner A, Lammers CH, Schmider J, Gotthardt U, Holsboer F, Heuser I: Low lumbar bone mineral density in patients with major depression. Am J Psychiatry 1994;151:1691–1693.
15.
Michelson D, Stratakis C, Hill L, Reynolds J, Galliven E, Chrousos G, Gold P: Bone mineral density in women with depression. N Engl J Med 1996;335:1176–1181.
16.
Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485–491.
17.
Yazici KM, Akinci A, Sutcu A, Ozcakar L: Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res 2003;117:271–275.
18.
Schweiger U, Weber B, Deuschle M, Heuser I: Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psychiatry 2000;157:118–120.
19.
Amsterdam J, Hooper M: Bone density measurement in major depression. Progr Neuropsychopharmacol Biol Psychiatry 1998;22:267–277.
20.
Yazici AE, Bagis S, Tot S, Sahin G, Yazici K, Erdogan C: Bone mineral density in premenopausal women with major depression. Joint Bone Spine 2005;72:540–543.
21.
Kavuncu V, Kuloglu M, Kaya A, Sahin S, Atmaca M, Firidin B: Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med J 2002;43:101–108.
22.
Reginster JY, Deroisy R, Paul I, Hansenne M, Ansseau M: Depressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women. Maturitas 1999;33:133–137.
23.
Jacka FN, Pasco JA, Henry MJ, Korn S, Williams LJ, Kotowicz MA, Nicholson GC, Berk M: Depression and bone mineral density in a community sample of men: Geelong Osteoporosis Study. J Mens Health Gend 2007;4:292–297.
24.
Jacka FN, Pasco JA, Henry MJ, Kotowicz MA, Dodd S, Nicholson GC, Berk M: Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study. Menopause 2005;12:88–91.
25.
Mussolino M, Jonas B, Looker A: Depression and bone mineral density in young adults: results from NHANES III. Psychosom Med 2004;66:533–537.
26.
Robbins J, Hirsch C, Whitmer R, Cauley J, Harris T: The association of bone mineral density and depression in an older population. J Am Geriatr Soc 2001;49:732–736.
27.
Wong SY, Lau EM, Lynn H, Leung PC, Woo J, Cummings SR, Orwoll E: Depression and bone mineral density: is there a relationship in elderly Asian men? Results from Mr. Os (Hong Kong). Osteoporos Int 2005;16:610–615.
28.
Whooley MA, Cauley JA, Zmuda JM, Haney EM, Glynn NW: Depressive symptoms and bone mineral density in older men. J Geriatr Psychiatry Neurol 2004;17:88–92.
29.
Diem SJ, Blackwell TL, Stone KL, Yaffe K, Cauley JA, Whooley MA, Ensrud KE: Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc 2007;55:824–831.
30.
Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A, Liu PY, Veldhuis JD: Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl 2007;433:90–103.
31.
Manelli F, Giustina A: Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000;11:79–85.
32.
Ziegler R, Kasperk C: Glucocorticoid- induced osteoporosis: prevention and treatment. Steroids 1998;63:344–348.
33.
Reynolds RM, Dennison EM, Walker BR, Syddall HE, Wood PJ, Andrew R, Phillips DI, Cooper C: Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif Tissue Int 2005;77:134–138.
34.
Dennison E, Hindmarsh P, Fall C, Kellingray S, Barker D, Phillips D, Cooper C: Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab 1999;84:3058–3063.
35.
Altindag O, Altindag A, Asoglu M, Gunes M, Soran N, Deveci Z: Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int J Clin Pract 2007;61:416–420.
36.
Furlan PM, Ten Have T, Cary M, Zemel B, Wehrli F, Katz IR, Gettes DR, Evans DL: The role of stress-induced cortisol in the relationship between depression and decreased bone mineral density. Biol Psychiatry 2005;57:911–917.
37.
Haberland M, Schilling AF, Rueger JM, Amling M: Brain and bone: central regulation of bone mass: a new paradigm in skeletal biology. J Bone Joint Surg Am 2001;83-A:1871–1876.
38.
Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197–207.
39.
Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TJ, Collier GR, Nicholson GC: Leptin inhibits osteoclast generation. J Bone Miner Res 2002;17:200–209.
40.
Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR: Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002;175:405–415.
41.
Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL: Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140:1630–1638.
42.
Pasco JA, Henry MJ, Kotowicz MA, Collier GR, Ball MJ, Ugoni AM, Nicholson GC: Serum leptin levels are associated with bone mass in nonobese women. J Clin Endocrinol Metab 2001;86:1884–1887.
43.
Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K: Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 2001;55:341–347.
44.
Iwamoto I, Douchi T, Kosha S, Murakami M, Fujino T, Nagata Y: Relationships between serum leptin level and regional bone mineral density, bone metabolic markers in healthy women. Acta Obstet Gynecol Scand 2000;79:1060–1064.
45.
Rauch F, Blum WF, Klein K, Allolio B, Schonau E: Does leptin have an effect on bone in adult women? Calcif Tissue Int 1998;63:453–455.
46.
Odabasi E, Ozata M, Turan M, Bingol N, Yonem A, Cakir B, Kutlu M, Ozdemir IC: Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol 2000;142:170–173.
47.
Ruhl CE, Everhart JE: Relationship of serum leptin concentration with bone mineral density in the United States population. J Bone Miner Res 2002;17:1896–1903.
48.
Jow GM, Yang TT, Chen CL: Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 2006;90:21–27.
49.
Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmacher T: Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001;73:243–247.
50.
Westling S, Ahren B, Traskman-Bendz L, Westrin A: Low CSF leptin in female suicide attempters with major depression. J Affect Disord 2004;81:41–48.
51.
Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Bayik Y: Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002;46:176–179.
52.
Deuschle M, Blum WF, Englaro P, Schweiger U, Weber B, Pflaum CD, Heuser I: Plasma leptin in depressed patients and healthy controls. Horm Metab Res 1996;28:714–717.
53.
Esel E, Ozsoy S, Tutus A, Sofuoglu S, Kartalci S, Bayram F, Kokbudak Z, Kula M: Effects of antidepressant treatment and of gender on serum leptin levels in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:565–570.
54.
Gecici O, Kuloglu M, Atmaca M, Tezcan AE, Tunckol H, Emul HM, Ustundag B: High serum leptin levels in depressive disorders with atypical features. Psychiatry Clin Neurosci 2005;59:736–738.
55.
Antonijevic IA, Murck H, Frieboes RM, Horn R, Brabant G, Steiger A: Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 1998;32:403–410.
56.
Pasco JA, Jacka FN, Williams LJ, Henry MJ, Nicholson GC, Kotowicz MA, Berk M: Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008;107:221–225.
57.
Ershler WB, Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000;51:245–270.
58.
Halbreich U, Palter S: Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996;22:447–454.
59.
Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201–217.
60.
Kiecolt-Glaser JK, Glaser R: Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002;53:873–876.
61.
Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370–379.
62.
Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A: Acute phase proteins in major depression. J Psychosom Res 1997;43:529–534.
63.
Connor TJ, Leonard BE: Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998;62:583–606.
64.
Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, Ayala AR, Licinio J, Gold HK, Kling MA, Chrousos GP, Gold PW: Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 2005;90:2522–2530.
65.
Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L, Harris T, Pahor M: Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition Study. Biol Psychiatry 2003;54:566–572.
66.
Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH: Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005;118:1414.
67.
Misra M, Papakostas GI, Klibanski A: Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607–1618; quiz 1590, 1760–1761.
68.
Poirier MF, Canceil O, Bayle F, Millet B, Bourdel MC, Moatti C, Olie JP, Attar-Levy D: Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:529–537.
69.
Hamalainen J, Kaprio J, Isometsa E, Heikkinen M, Poikolainen K, Lindeman S, Aro H: Cigarette smoking, alcohol intoxication and major depressive episode in a representative population sample. J Epidemiol Community Health 2001;55:573–576.
70.
Brown RA, Lewinsohn PM, Seeley JR, Wagner EF: Cigarette smoking, major depression, and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1602–1610.
71.
Klungsoyr O, Nygard JF, Sorensen T, Sandanger I: Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 2006;163:421–432.
72.
Steuber TL, Danner F: Adolescent smoking and depression: which comes first? Addict Behav 2006;31:133–136.
73.
Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P: Major depression and stages of smoking: a longitudinal investigation. Arch Gen Psychiatry 1998;55:161–166.
74.
Quattrocki E, Baird A, Yurgelun-Todd D: Biological aspects of the link between smoking and depression. Harv Rev Psychiatry 2000;8:99–110.
75.
Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL: Smoking and bone metabolism in elderly women. Bone 2000;27:429–436.
76.
Hopper JL, Seeman E: The bone density of female twins discordant for tobacco use. N Engl J Med 1994;330:387–392.
77.
Akhter MP, Lund AD, Gairola CG: Bone biomechanical property deterioration due to tobacco smoke exposure. Calcif Tissue Int 2005;77:319–326.
78.
Baheiraei A, Pocock NA, Eisman JA, Nguyen ND, Nguyen TV: Bone mineral density, body mass index and cigarette smoking among Iranian women: implications for prevention. BMC Musculoskelet Disord 2005;6:34.
79.
Lorentzon M, Mellstrom D, Haug E, Ohlsson C: Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007;92:497–503.
80.
Gerdhem P, Obrant KJ: Effects of cigarette-smoking on bone mass as assessed by dual-energy X-ray absorptiometry and ultrasound. Osteoporos Int 2002;13:932–936.
81.
Sullivan LE, Fiellin DA, O’Connor PG: The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med 2005;118:330–341.
82.
De Graaf R, Bijl RV, Spijker J, Beekman AT, Vollebergh WA: Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders – findings from the Netherlands Mental Health Survey and Incidence Study. Soc Psychiatry Psychiatr Epidemiol 2003;38:1–11.
83.
Dixit AR, Crum RM: Prospective study of depression and the risk of heavy alcohol use in women. Am J Psychiatry 2000;157:751–758.
84.
Heinz A, Mann K, Weinberger DR, Goldman D: Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res 2001;25:487–495.
85.
Nevo I, Hamon M: Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995;26:305–336; discussion 337–342.
86.
Lukassen J, Beaudet MP: Alcohol dependence and depression among heavy drinkers in Canada. Soc Sci Med 2005;61:1658–1667.
87.
Crum RM, Brown C, Liang KY, Eaton WW: The association of depression and problem drinking: analyses from the Baltimore ECA follow-up study – Epidemiologic Catchment Area. Addict Behav 2001;26:765–773.
88.
Chakkalakal DA: Alcohol-induced bone loss and deficient bone repair. Alcohol Clin Exp Res 2005;29:2077–2090.
89.
Turner RT, Sibonga JD: Effects of alcohol use and estrogen on bone. Alcohol Res Health 2001;25:276–281.
90.
Turner RT: Skeletal response to alcohol. Alcohol Clin Exp Res 2000;24:1693–1701.
91.
Williams FM, Cherkas LF, Spector TD, MacGregor AJ: The effect of moderate alcohol consumption on bone mineral density: a study of female twins. Ann Rheum Dis 2005;64:309–310.
92.
Register TC, Cline JM, Shively CA: Health issues in postmenopausal women who drink. Alcohol Res Health 2002;26:299–307.
93.
Rapuri PB, Gallagher JC, Balhorn KE, Ryschon KL: Alcohol intake and bone metabolism in elderly women. Am J Clin Nutr 2000;72:1206–1213.
94.
Feskanich D, Korrick SA, Greenspan SL, Rosen HN, Colditz GA: Moderate alcohol consumption and bone density among postmenopausal women. J Womens Health 1999;8:65–73.
95.
Hoidrup S, Gronbaek M, Gottschau A, Lauritzen JB, Schroll M, Copenhagen Centre for Prospective Population Studies: Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 1999;149:993–1001.
96.
Van Gool CH, Kempen GI, Penninx BW, Deeg DJ, Beekman AT, van Eijk JT: Relationship between changes in depressive symptoms and unhealthy lifestyles in late middle-aged and older persons: results from the Longitudinal Aging Study Amsterdam. Age Ageing 2003;32:81–87.
97.
Weyerer S: Physical inactivity and depression in the community: evidence from the Upper Bavarian Field Study. Int J Sports Med 1992;13:492–496.
98.
Farmer ME, Locke BZ, Moscicki EK, Dannenberg AL, Larson DB, Radloff LS: Physical activity and depressive symptoms: the NHANES I Epidemiologic Follow-Up Study. Am J Epidemiol 1988;128:1340–1351.
99.
Morgan K, Bath PA: Customary physical activity and psychological well-being: a longitudinal study. Age Ageing 1998;27(suppl 3):35–40.
100.
Trivedi MH, Greer TL, Grannemann BD, Chambliss HO, Jordan AN: Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract 2006;12:205–213.
101.
Dimeo F, Bauer M, Varahram I, Proest G, Halter U: Benefits from aerobic exercise in patients with major depression: a pilot study. Br J Sports Med 2001;35:114–117.
102.
Peluso MA, Andrade LH: Physical activity and mental health: the association between exercise and mood. Clinics 2005;60:61–70.
103.
Paluska SA, Schwenk TL: Physical activity and mental health: current concepts. Sports Med 2000;29:167–180.
104.
Bakhireva LN, Barrett-Connor E, Kritz-Silverstein D, Morton DJ: Modifiable predictors of bone loss in older men: a prospective study. Am J Prev Med 2004;26:436–442.
105.
Snelling AM, Crespo CJ, Schaeffer M, Smith S, Walbourn L: Modifiable and nonmodifiable factors associated with osteoporosis in postmenopausal women: results from the Third National Health and Nutrition Examination Survey, 1988–1994. J Womens Health Gend Based Med 2001;10:57–65.
106.
Ho AY, Kung AW: Determinants of peak bone mineral density and bone area in young women. J Bone Miner Metab 2005;23:470–475.
107.
MacInnis RJ, Cassar C, Nowson CA, Paton LM, Flicker L, Hopper JL, Larkins RG, Wark JD: Determinants of bone density in 30- to 65-year-old women: a co-twin study. J Bone Miner Res 2003;18:1650–1656.
108.
Murphy NM, Carroll P: The effect of physical activity and its interaction with nutrition on bone health. Proc Nutr Soc 2003;62:829–838.
109.
Gerdhem P, Ringsberg KA, Akesson K, Obrant KJ: Influence of muscle strength, physical activity and weight on bone mass in a population-based sample of 1004 elderly women. Osteoporos Int 2003;14:768–772.
110.
Turner LW, Bass MA, Ting L, Brown B: Influence of yard work and weight training on bone mineral density among older US women. J Women Aging 2002;14:139–148.
111.
New SA: Exercise, bone and nutrition. Proc Nutr Soc 2001;60:265–274.
112.
Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D: Omega-3 fatty acids and mood disorders. Am J Psychiatry 2006;163:969–978.
113.
Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P: Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 2004;82:447–452.
114.
Hashizume N, Mori M: An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med 1990;29:368–372.
115.
Zieba A, Kata R, Dudek D, Schlegel-Zawadzka M, Nowak G: Serum trace elements in animal models and human depression. III. Magnesium: relationship with copper. Hum Psychopharmacol 2000;15:631–635.
116.
Berk M, Sanders KM, Pasco JA, Jacka FN, Williams LJ, Hayles AL, Dodd S: Vitamin D deficiency may play a role in depression. Med Hypotheses 2007;69:1316–1319.
117.
Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC: Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 2006;14:1032–1040.
118.
Poleszak E, Szewczyk B, Kedzierska E, Wlaz P, Pilc A, Nowak G: Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 2004;78:7–12.
119.
Eby GA, Eby KL: Rapid recovery from major depression using magnesium treatment. Med Hypotheses 2006;67:362–370.
120.
Lansdowne AT, Provost SC: Vitamin D3 enhances mood in healthy subjects during winter. Psychopharmacology (Berl) 1998;135:319–323.
121.
Tolmunen T, Hintikka J, Ruusunen A, Voutilainen S, Tanskanen A, Valkonen VP, Viinamaki H, Kaplan GA, Salonen JT: Dietary folate and the risk of depression in Finnish middle-aged men: a prospective follow-up study. Psychother Psychosom 2004;73:334–339.
122.
Coppen A, Bolander-Gouaille C: Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59–65.
123.
Hvas AM, Juul S, Bech P, Nexo E: Vitamin B6 level is associated with symptoms of depression. Psychother Psychosom 2004;73:340–343.
124.
Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A: Lower serum vitamin E concentrations in major depression: another marker of lowered antioxidant defenses in that illness. J Affect Disord 2000;58:241–246.
125.
Zalloua PA, Hsu YH, Terwedow H, Zang T, Wu D, Tang G, Li Z, Hong X, Azar ST, Wang B, Bouxsein ML, Brain J, Cummings SR, Rosen CJ, Xu X: Impact of seafood and fruit consumption on bone mineral density. Maturitas 2007;56:1–11.
126.
Tranquilli AL, Lucino E, Garzetti GG, Romanini C: Calcium, phosphorus and magnesium intakes correlate with bone mineral content in postmenopausal women. Gynecol Endocrinol 1994;8:55–58.
127.
Dimai HP, Porta S, Wirnsberger G, Lindschinger M, Pamperl I, Dobnig H, Wilders-Truschnig M, Lau KH: Daily oral magnesium supplementation suppresses bone turnover in young adult males. J Clin Endocrinol Metab 1998;83:2742–2748.
128.
Sojka JE, Weaver CM: Magnesium supplementation and osteoporosis. Nutr Rev 1995;53:71–74.
129.
Tucker KL, Hannan MT, Chen H, Cupples LA, Wilson PW, Kiel DP: Potassium, magnesium, and fruit and vegetable intakes are associated with greater bone mineral density in elderly men and women. Am J Clin Nutr 1999;69:727–736.
130.
Palacios C: The role of nutrients in bone health, from A to Z. Crit Rev Food Sci Nutr 2006;46:621–628.
131.
Warden SJ, Bliziotes MM, Wiren KM, Eshleman AJ, Turner CH: Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 2005;242:1–9.
132.
Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ: Expression of serotonin receptors in bone. J Biol Chem 2001;276:28961–28968.
133.
Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligard E, Brunsvik A, Dimmen S, van Leeuwen JP, Weinans H, Syversen U: Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 2006;97:1283–1291.
134.
Gustafsson BI, Waarsing E, Stunes K, Thommesen L, Waldum H, van Leeuwen H, Syversen U, Weinens H, Westbroek I: Anti-depressants, depressing effects on bone? J Bone Miner Res 2005;20:S113.
135.
Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH: Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005;146:685–693.
136.
Williams LW, Henry M, Berk M, Dodd S, Jacka FN, Kotowicz MA, Nicholson GC, Pasco JA: Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008;23:84–87.
137.
Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E, Ensrud K, Lau EM, Orwoll ES: Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 2005;16:1525–1537.
138.
Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167:1246–1251.
139.
Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney EM, Bliziotes MM, Ensrud KE: Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007;167:1240–1245.
140.
Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, Goltzman D: Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007;167:188–194.
141.
Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC, Whooley MA: Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003;163:949–957.
142.
Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A: Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003;158:77–84.
143.
Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N: Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303–1307.
144.
Takkouche B, Montes-Martinez A, Gill SS, Etminan M: Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007;30:171–184.
145.
Leipzig RM, Cumming RG, Tinetti ME: Drugs and falls in older people: a systematic review and meta-analysis. I. Psychotropic drugs. J Am Geriatr Soc 1999;47:30–39.
146.
Chaimowicz F, Ferreira Tde J, Miguel DF: Use of psychoactive drugs and related falls among older people living in a community in Brazil. Rev Saude Publica 2000;34:631–635.
147.
Ray WA, Thapa PB, Gideon P: Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 2000;48:682–685.
148.
Maxwell CJ, Neutel CI, Hirdes JP: A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf 1997;6:27–35.
149.
Maguire GA: Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63(suppl 4):56–62.
150.
O’Keane V, Meaney AM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25:26–31.
151.
Meaney AM, Smith S, Howes OD, O’Brien M, Murray RM, O’Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503–508.
152.
Madhusmita M, Papakostas G, Klibanski A: Effects of psychiatric disorders and psychotropic medication on prolactin and bone metabolism. J Clin Psychiatry 2004;65:1607–1618.
153.
Halbreich U, Kahn LS: Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 2003;9:344–353.
154.
Sonino N, Fava GA: Rehabilitation in endocrine patients: a novel psychosomatic approach. Psychother Psychosom 2007;76:319–324.
155.
Jacka F, Berk M: Food for thought. Acta Neuropsychiatr 2007;19:321–323.
156.
Berk M: Should we be targeting exercise as a routine mental health intervention? Acta Neuropsychiatr 2007;19:217–218.
157.
Berk M: Should we be targeting smoking as a routine intervention? Acta Neuropsychiatr 2007;19:131–132.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.